publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Edoxaban
R2-CHA2DS2-VASc score for cardiovascular event prediction after bioprosthetic valve replacement: Subanalysis from the BPV-AF registry
Valemetostat
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer
Dato-DXd, DS-1103, Other/Multi
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
Edoxaban
Application of the win ratio method in the ENGAGE AF-TIMI 48 trial comparing edoxaban with warfarin in patients with atrial fibrillation
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial
Edoxaban
Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer: A plain language summary of the DESTINY-Breast03 study
T-DXd
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Other/Multi
Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: A review